Literature DB >> 9773960

Establishment of monoclonal antibody against human Apo B-48 and measurement of Apo B-48 in serum by ELISA method.

Y Uchida1, Y Kurano, S Ito.   

Abstract

The elevation of chylomicrons and chylomicron remnants in plasma would lead to hyperlipidemia and other complications. Apo B-48, which is translated and produced in the adult intestine from the same gene as Apo B-100, is considered to be an essential component of chylomicrons and chylomicron remnants. Using a peptide representing human Apo B-48 C-terminal sequence as immunogen, we established a monoclonal antibody, B48-151, against human Apo B-48. The specific reactivity for Apo B-48 of this monoclonal antibody was confirmed using Western blot analysis of human plasma in fractions isolated as chylomicron and VLDL. Then, we developed a simple sandwich ELISA method for the detection of human Apo B-48 in serum by combining B48-151 as capturing antibody and HRP-conjugated-polyclonal antibodies for Apo B as signaling antibody. The established sandwich ELISA constitutes a simple method to monitorApo B-48 level in chylomicrons and chylomicron remnants in human serum.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9773960      PMCID: PMC6807790          DOI: 10.1002/(sici)1098-2825(1998)12:5<289::aid-jcla7>3.0.co;2-1

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  12 in total

1.  A highly sensitive assay for quantitation of apolipoprotein B48 using an antibody to human apolipoprotein B and enhanced chemiluminescence.

Authors:  D Smith; S D Proctor; J C Mamo
Journal:  Ann Clin Biochem       Date:  1997-03       Impact factor: 2.057

2.  The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum.

Authors:  R J HAVEL; H A EDER; J H BRAGDON
Journal:  J Clin Invest       Date:  1955-09       Impact factor: 14.808

3.  Sequence, structure, receptor-binding domains and internal repeats of human apolipoprotein B-100.

Authors:  C Y Yang; S H Chen; S H Gianturco; W A Bradley; J T Sparrow; M Tanimura; W H Li; D A Sparrow; H DeLoof; M Rosseneu
Journal:  Nature       Date:  1986 Oct 23-29       Impact factor: 49.962

Review 4.  Formation and metabolism of chylomicrons.

Authors:  T G Redgrave
Journal:  Int Rev Physiol       Date:  1983

5.  A novel form of tissue-specific RNA processing produces apolipoprotein-B48 in intestine.

Authors:  L M Powell; S C Wallis; R J Pease; Y H Edwards; T J Knott; J Scott
Journal:  Cell       Date:  1987-09-11       Impact factor: 41.582

6.  Apolipoprotein B-48 is the product of a messenger RNA with an organ-specific in-frame stop codon.

Authors:  S H Chen; G Habib; C Y Yang; Z W Gu; B R Lee; S A Weng; S R Silberman; S J Cai; J P Deslypere; M Rosseneu
Journal:  Science       Date:  1987-10-16       Impact factor: 47.728

7.  Elimination of apolipoprotein B48 formation in rat hepatoma cell lines transfected with mutant human apolipoprotein B cDNA constructs.

Authors:  Z M Yao; B D Blackhart; D F Johnson; S M Taylor; K W Haubold; B J McCarthy
Journal:  J Biol Chem       Date:  1992-01-15       Impact factor: 5.157

8.  A novel antiserum specific to apolipoprotein B-48: application in the investigation of postprandial lipidaemia in humans.

Authors:  A S Peel; A Zampelas; C M Williams; B J Gould
Journal:  Clin Sci (Lond)       Date:  1993-11       Impact factor: 6.124

9.  Postprandial intestinal-derived chylomicron and chylomicron remnants in essential hypertensive patients before and after prolonged captopril therapy.

Authors:  A Iaina; D S Silverberg; Y Wollman; R Judevics; R Baruch; C Levhar; G Peer; M Blum; I Grosskopf; M S Weintraub
Journal:  Am J Hypertens       Date:  1995-01       Impact factor: 2.689

10.  Expression of carboxyl-terminally truncated forms of human apolipoprotein B in rat hepatoma cells. Evidence that the length of apolipoprotein B has a major effect on the buoyant density of the secreted lipoproteins.

Authors:  Z M Yao; B D Blackhart; M F Linton; S M Taylor; S G Young; B J McCarthy
Journal:  J Biol Chem       Date:  1991-02-15       Impact factor: 5.157

View more
  6 in total

Review 1.  Postprandial lipoprotein metabolism: VLDL vs chylomicrons.

Authors:  Katsuyuki Nakajima; Takamitsu Nakano; Yoshiharu Tokita; Takeaki Nagamine; Akihiro Inazu; Junji Kobayashi; Hiroshi Mabuchi; Kimber L Stanhope; Peter J Havel; Mitsuyo Okazaki; Masumi Ai; Akira Tanaka
Journal:  Clin Chim Acta       Date:  2011-04-19       Impact factor: 3.786

2.  Fasting and postprandial apolipoprotein B-48 levels in healthy, obese, and hyperlipidemic subjects.

Authors:  Seiko Otokozawa; Masumi Ai; Margaret R Diffenderfer; Bela F Asztalos; Akira Tanaka; Stefania Lamon-Fava; Ernst J Schaefer
Journal:  Metabolism       Date:  2009-07-09       Impact factor: 8.694

3.  Chronic kidney disease delays VLDL-apoB-100 particle catabolism: potential role of apolipoprotein C-III.

Authors:  Doris T Chan; Gursharan K Dogra; Ashley B Irish; Esther M Ooi; P Hugh Barrett; Dick C Chan; Gerald F Watts
Journal:  J Lipid Res       Date:  2009-06-21       Impact factor: 5.922

4.  A Novel Selective PPARα Modulator (SPPARMα), K-877 (Pemafibrate), Attenuates Postprandial Hypertriglyceridemia in Mice.

Authors:  Masami Sairyo; Takuya Kobayashi; Daisaku Masuda; Koutaro Kanno; Yinghong Zhu; Takeshi Okada; Masahiro Koseki; Tohru Ohama; Makoto Nishida; Yasushi Sakata; Shizuya Yamashita
Journal:  J Atheroscler Thromb       Date:  2017-08-05       Impact factor: 4.928

5.  Lysophosphatidylcholine for efficient intestinal lipid absorption and lipoprotein secretion in caco-2 cells.

Authors:  Takanari Nakano; Ikuo Inoue; Shigehiro Katayama; Makoto Seo; Seiichiro Takahashi; Shigeru Hokari; Rina Shinozaki; Kazuhisa Hatayama; Tsugikazu Komoda
Journal:  J Clin Biochem Nutr       Date:  2009-08-28       Impact factor: 3.114

Review 6.  Postprandial Hyperlipidemia and Remnant Lipoproteins.

Authors:  Daisaku Masuda; Shizuya Yamashita
Journal:  J Atheroscler Thromb       Date:  2016-11-08       Impact factor: 4.928

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.